BlueWillow Biologics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Ann Arbor MI United States (1999)

Organization Overview

First Clinical Trial
2007
NCT00453271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BlueWillow Biologics | Okati Research Center, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 1)

Herpes Labialis (Phase 3)

Herpes Simplex (Phase 3)

Onychomycosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8